ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,000
-1,190 (-7.35%)
Mar 9, 2026, 3:30 PM KST
-15.01%
Market Cap 164.47B
Revenue (ttm) 5.91B
Net Income (ttm) -17.78B
Shares Out 10.96M
EPS (ttm) -1,643.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 126,491
Average Volume 389,180
Open 15,430
Previous Close 16,190
Day's Range 14,680 - 15,780
52-Week Range 10,000 - 20,950
Beta n/a
RSI 43.43
Earnings Date n/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2024, ENCell's revenue was 7.21 billion, a decrease of -31.51% compared to the previous year's 10.53 billion. Losses were -15.21 billion, 201.0% more than in 2023.

Financial Statements

News

There is no news available yet.